Pharmacology & ToxicologybioRxiv
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
R. M. Barfield, Y. C. Kim, S. Chuprakov…·P. M. Drake
This paper develops a novel HER2-targeted ADC, CAT-01-106, showing improved efficacy and tolerability compared to T-DM1 at equivalent payload dosing.